Despite decades of advancements in reproductive health, male contraception methods remain limited to condoms or vasectomies. This leaves few options for those seeking alternatives and leaves women shouldering the physical and hormonal burdens of birth control. Today, with 85% of men aged 18–45 actively seeking new family planning solutions, the demand for a long-acting, reversible alternative is greater than ever.    As male contraception advances in the wake of the Dobbs decision reversal, this episode examines market prospects, regulatory hurdles, and the future of reproductive options for men.    Featuring: Darlene Walley, Chief Executive Officer, NEXT Life Sciences     In this episode, we will cover…  The growing demand for male contraception in the wake of shifting reproductive rights policies.  How Vasalgel technology works and why it's a reversible alternative to vasectomies.  The regulatory approval pathway for Plan A as a medical device.  The economic and public health impact of expanded contraceptive options for men.  The role of strategic partnerships with organizations like Planned Parenthood and the Male Contraceptive Initiative in advancing male birth control.    To stay up to date on the latest developments in male contraception, check out our Pharma Life Sciences sites.     To watch video clips from the conversation, subscribe to our YouTube channel, @HealthcareStrategies.    References:  U.S. men's interest in new male contraceptives  A reversible alternative to vasectomies  Pipeline of male contraceptives